2024年8月2日，圣诺生物获华福证券买入评级，近一个月圣诺生物获得4份研报关注。
研报预计公司2024-2026年归母净利润分别为1/1.4/1.7亿元，同比增长42%/39%/21%，公司成长性凸显。研报认为，随着新产能落地，公司在未来3-5年的研发工作将顺利开展，并有望驱动业绩持续增长。
风险提示：产能扩张不及预期、原料药及CDMO业务下游订单不及预期、制剂价格及毛利率下降超预期风险。
- Headlines
- 圣诺生物获华福证券买入评级，产能落地在即
圣诺生物获华福证券买入评级，产能落地在即
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Hot News
Updated
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.